This document provides an agenda for the ISAD 2012 conference taking place from April 18-20th at the Royal College of Physicians in London. The conference consists of symposia on various topics related to affective disorders on the first two days, including sessions on bipolar disorder and substance abuse, brain stimulation methods for treating depression, and mood disorders and somatic comorbidity. There will also be keynote speeches, poster presentations, satellite symposiums and oral presentation sessions. The agenda outlines the schedule, locations and speakers for each session.
Psychiatry and Physical Health: Monitoring and managing physical health needs...infobipolar
Programa científico de la conferencia de Psychiatry and Physical Health: Monitoring and managing physical health needs in mental health. Más información en www.puedoser.es
The document provides the proposed programme for the 12th International Review of Bipolar Disorders conference being held from May 21-23, 2012 in Nice, France. The conference will include plenary sessions, scientific updates, debates, and interactive sessions on topics related to bipolar disorders, including classification, assessment, management of difficult cases, pathophysiology, and treatment. Presenters will discuss findings from recent research studies. Poster viewing and presentations are also included in the program over the three day event.
El documento describe el programa de un foro internacional sobre innovación clínica y su impacto en la gestión sanitaria llamado MIHealth que se llevará a cabo del 24 al 25 de mayo de 2012 en Barcelona. El foro incluirá conferencias plenarias, exposiciones comerciales, eventos paralelos y cuatro tracks principales sobre temas como conocimiento clínico e innovación, tecnologías para la transformación del sistema sanitario, innovación en la gestión de organizaciones sanitarias y
Programa sobre Trastorno Bipolar del 26 ECNP Barcelona 2013infobipolar
This document contains information about several symposium sessions occurring at a conference on major depressive disorder and bipolar disorder. It lists the titles, presenters, times and locations for sessions on prioritizing patients in managing major depressive disorder, bipolar disorder and its evolving understanding, the multidimensional perspective of bipolar I disorder, and genetic implications in bipolar disorder. The genetic implications session includes four presentations on pharmacogenetics related to treatment of bipolar disorder and genetics of suicidal behavior.
The document outlines the scientific program for the ISBD 2014 conference held from March 18-21. It includes details of the schedule each day, listing various sessions in different halls and theaters including keynote lectures, symposia tracks on treatment, clinical manifestations, neurobiology, imaging and culture. Sample session topics include lithium treatment, bipolar disorder in children, neuroendocrine challenges, metabolic syndrome, psychosocial treatments and advocacy.
22 European Congress of Psychiatry Munich 2014infobipolar
The document provides the schedule for the Academia Educational Course taking place on March 1-4. The schedule lists the various rooms where sessions will be held, along with session titles and times. Some of the session topics include problem solving in psychopharmacotherapy, motivational interviewing in addiction, medical error prevention, and evaluations of suicidal risk. Coffee breaks are scheduled daily and there is a welcome reception on the evening of March 1st.
Psychiatry and Physical Health: Monitoring and managing physical health needs...infobipolar
Programa científico de la conferencia de Psychiatry and Physical Health: Monitoring and managing physical health needs in mental health. Más información en www.puedoser.es
The document provides the proposed programme for the 12th International Review of Bipolar Disorders conference being held from May 21-23, 2012 in Nice, France. The conference will include plenary sessions, scientific updates, debates, and interactive sessions on topics related to bipolar disorders, including classification, assessment, management of difficult cases, pathophysiology, and treatment. Presenters will discuss findings from recent research studies. Poster viewing and presentations are also included in the program over the three day event.
El documento describe el programa de un foro internacional sobre innovación clínica y su impacto en la gestión sanitaria llamado MIHealth que se llevará a cabo del 24 al 25 de mayo de 2012 en Barcelona. El foro incluirá conferencias plenarias, exposiciones comerciales, eventos paralelos y cuatro tracks principales sobre temas como conocimiento clínico e innovación, tecnologías para la transformación del sistema sanitario, innovación en la gestión de organizaciones sanitarias y
Programa sobre Trastorno Bipolar del 26 ECNP Barcelona 2013infobipolar
This document contains information about several symposium sessions occurring at a conference on major depressive disorder and bipolar disorder. It lists the titles, presenters, times and locations for sessions on prioritizing patients in managing major depressive disorder, bipolar disorder and its evolving understanding, the multidimensional perspective of bipolar I disorder, and genetic implications in bipolar disorder. The genetic implications session includes four presentations on pharmacogenetics related to treatment of bipolar disorder and genetics of suicidal behavior.
The document outlines the scientific program for the ISBD 2014 conference held from March 18-21. It includes details of the schedule each day, listing various sessions in different halls and theaters including keynote lectures, symposia tracks on treatment, clinical manifestations, neurobiology, imaging and culture. Sample session topics include lithium treatment, bipolar disorder in children, neuroendocrine challenges, metabolic syndrome, psychosocial treatments and advocacy.
22 European Congress of Psychiatry Munich 2014infobipolar
The document provides the schedule for the Academia Educational Course taking place on March 1-4. The schedule lists the various rooms where sessions will be held, along with session titles and times. Some of the session topics include problem solving in psychopharmacotherapy, motivational interviewing in addiction, medical error prevention, and evaluations of suicidal risk. Coffee breaks are scheduled daily and there is a welcome reception on the evening of March 1st.
This document provides an overview of brain stimulation strategies for obsessive-compulsive disorder (OCD). It begins with definitions and classifications of OCD according to DSM-5 and ICD-11 criteria. It then discusses the neurobiology of OCD including abnormalities in frontostriatal circuits. Treatment modalities covered include pharmacotherapy with SSRIs, psychotherapy such as exposure therapy, and brain stimulation methods like transcranial magnetic stimulation and deep brain stimulation. Mechanisms of action and comparisons between brain stimulation and pharmacotherapy are also presented. The document provides context on neuromodulation therapies and their role in treating psychiatric disorders through targeted brain stimulation.
This document provides information about a presentation given by Dr. Louis B. Cady on transcranial magnetic stimulation (TMS) as a treatment for depression. It begins with Dr. Cady's credentials and commercial disclosure stating he has received honoraria from several companies but that this presentation is not being underwritten by any company. The presentation then covers how TMS works, its safety and effectiveness compared to antidepressant medications and electroconvulsive therapy (ECT), and its inclusion in treatment guidelines for depression.
Magnets - Not Drugs: TMS IMMH San Antonio 2014Louis Cady, MD
In this talk, Dr. Cady covers a remarkable new treatment for depression: transcranial magnetic stimulation. The historical roots of this treatment are traced, followed by a review of the literature in terms of the proven efficacy of this treatment. A comparison with ECT shows that TMS has a very favorable profile, with remarkably fewer side effects and incredibly better tolerated side effects compared to ECT. Given that this was a "CME" talk, off-label uses of TMS were reviewed, including stepping stones for future avenues to explore
The presentation part of a two-day workshop on ECT held at al-Hussain University Hospital of al-Azhar Univeristy. It was accompanied by one-to-one training on the Thymatron system IV machine in the ECT suite of al-Hussain hospital.
The document provides an overview of bipolar disorder, including its prevalence, symptoms, diagnosis, course, treatment guidelines, and monitoring recommendations. It discusses the symptomatology and classification of bipolar I and II disorders. It also outlines the etiology, neurobiology, and risk of relapse associated with bipolar disorder. Treatment guidelines from NICE focus on acute stabilization and long-term management using lithium, anticonvulsants, or antipsychotics.
1) Antipsychotic drugs, especially high-potency first-generation antipsychotics, can cause acute dystonia in up to 10% of cases, with symptoms appearing within 96 hours of starting or increasing the dose of the antipsychotic medication.
2) Acute dystonia is characterized by sustained muscle contractions causing abnormal postures and twisting movements of parts of the body. It is considered a medical emergency.
3) Treatment involves stopping the offending antipsychotic medication and administering anticholinergic medications like trihexyphenidyl, which relieve symptoms in the majority of cases within hours. Prompt treatment is important to prevent any long-term effects.
Goldman grand rounds, electroconvulsive therapy (ect)...mysterious rebootLisa E Goldman, MD, MSW
How does ECT work? Is it dangerous? Is it scary? Does it work? What mental health conditions can be effectively treated by ECT? Is it true that ECT works better than prescription antidepressants? What are common side effects of ECT and how are this managed? Has the practice of ECT changed over time? What patient factors are the best predictors of positive and negative outcomes of ECT treatment? Come with me on a journey as I present my grand rounds lecture for the department of psychiatry as I complete my 4th year of psychiatry residency at UTHSC Memphis. These are exciting times. Recovery is definitely an option.
Dr. Claudia Mghazli examines how osteopathic manual therapy can aid with tinnitus, a condition that affects an estimated 10-15% of the global population.
BIOLOGICAL EFFECTS OF RADIATION USHA YADAV.pptxSubamProjects
Basic of human body
What is biological effect of radiation
How radiation can cause biological damage
Factors affecting biological effects
What are classes different biological effects caused by radiation
Acute radiation syndrome
Partial body effects
Cancer and genetic risk
DR SANJAY PHADKE- Introducing Symposium on MIND- BODY MEDICINEDR VANI KULHALLI
The critical importance of mind body medicine as regards
- treatment gap of 80-96pc for mental illness
- proved benefit
- can be administered by non medical professionals
- safe and efficetive
This document summarizes research on oxytocin and its effects on heart rate variability and social behavior. It discusses how oxytocin increases gaze to eye regions and is involved in emotion recognition. Oxytocin has also been shown to increase heart rate variability, which is reduced in conditions like depression and alcohol dependence. The document proposes a placebo-controlled study using oxytocin treatment over 4 weeks for alcohol dependence, measuring outcomes like alcohol intake, social cognition, and psychophysiology. It suggests oxytocin may help disorders with poor social functioning by influencing the autonomic nervous system.
Transcranial magnetic stimulation (TMS) is a non-invasive treatment for major depressive disorder that uses magnetic pulses to stimulate nerve cells in the brain. A review of the efficacy of TMS found that it is an effective alternative or addition to treatments like antidepressants and psychotherapy. TMS works by inducing electric currents in the brain via electromagnetic induction to modulate neuronal activity. It has shown response rates of about 60% in clinical trials with mostly mild side effects like brief scalp discomfort. TMS may help reduce the burden of depression, which is high in India, by providing an additional treatment option.
- Mental depression can now be treated safely without drugs or side effects using a new 5-minute treatment called CellSonic that uses shockwaves.
- Pharmaceutical antidepressants cause permanent brain damage with long-term use and risk drug dependency, whereas CellSonic has no side effects.
- Two professors from Poland reported feeling lifted, relaxed, and happier after CellSonic treatments, indicating it may have antidepressant effects by stimulating neurons in the brain.
Prophylaxis,Treatment of Acute Toxic Radiation Cerebrovascular Syndrome Asso...Dmitri Popov
This document discusses acute cerebrovascular radiation syndrome associated with long-term space flight to Mars. It describes the potential risks of radiation exposure during space travel, including the development of radiation neurotoxins that can disrupt the blood-brain barrier and blood flow. It then presents a grading system for acute cerebrovascular radiation syndrome based on neurological symptoms. Finally, it discusses the roles of cannabinoids and their receptors in potentially helping to prevent or treat the biological effects of radiation exposure.
Protection of humans during long space flight. using cannabis to reduce biol...Dmitri Popov
Protection of humans during long space flight. using cannabis to reduce biological consequences of high doses of radiation, treat stress, anxiety, and depression Associated with Long-term Space Flight to Mars.
Know Alzheimer. Manual de consulta para neurólogosinfobipolar
Los nuevos criterios diagnósticos de la demencia debida a la enfermedad de Alzheimer de la NIA-AA aportan cuatro mejoras principales respecto a los criterios NINCS-ADRDA: 1) no establecen un límite de edad, 2) incluyen el concepto de deterioro cognitivo leve, 3) consideran la conducta como un criterio independiente y 4) incorporan la probabilidad diagnóstica basada en biomarcadores.
This document provides an overview of brain stimulation strategies for obsessive-compulsive disorder (OCD). It begins with definitions and classifications of OCD according to DSM-5 and ICD-11 criteria. It then discusses the neurobiology of OCD including abnormalities in frontostriatal circuits. Treatment modalities covered include pharmacotherapy with SSRIs, psychotherapy such as exposure therapy, and brain stimulation methods like transcranial magnetic stimulation and deep brain stimulation. Mechanisms of action and comparisons between brain stimulation and pharmacotherapy are also presented. The document provides context on neuromodulation therapies and their role in treating psychiatric disorders through targeted brain stimulation.
This document provides information about a presentation given by Dr. Louis B. Cady on transcranial magnetic stimulation (TMS) as a treatment for depression. It begins with Dr. Cady's credentials and commercial disclosure stating he has received honoraria from several companies but that this presentation is not being underwritten by any company. The presentation then covers how TMS works, its safety and effectiveness compared to antidepressant medications and electroconvulsive therapy (ECT), and its inclusion in treatment guidelines for depression.
Magnets - Not Drugs: TMS IMMH San Antonio 2014Louis Cady, MD
In this talk, Dr. Cady covers a remarkable new treatment for depression: transcranial magnetic stimulation. The historical roots of this treatment are traced, followed by a review of the literature in terms of the proven efficacy of this treatment. A comparison with ECT shows that TMS has a very favorable profile, with remarkably fewer side effects and incredibly better tolerated side effects compared to ECT. Given that this was a "CME" talk, off-label uses of TMS were reviewed, including stepping stones for future avenues to explore
The presentation part of a two-day workshop on ECT held at al-Hussain University Hospital of al-Azhar Univeristy. It was accompanied by one-to-one training on the Thymatron system IV machine in the ECT suite of al-Hussain hospital.
The document provides an overview of bipolar disorder, including its prevalence, symptoms, diagnosis, course, treatment guidelines, and monitoring recommendations. It discusses the symptomatology and classification of bipolar I and II disorders. It also outlines the etiology, neurobiology, and risk of relapse associated with bipolar disorder. Treatment guidelines from NICE focus on acute stabilization and long-term management using lithium, anticonvulsants, or antipsychotics.
1) Antipsychotic drugs, especially high-potency first-generation antipsychotics, can cause acute dystonia in up to 10% of cases, with symptoms appearing within 96 hours of starting or increasing the dose of the antipsychotic medication.
2) Acute dystonia is characterized by sustained muscle contractions causing abnormal postures and twisting movements of parts of the body. It is considered a medical emergency.
3) Treatment involves stopping the offending antipsychotic medication and administering anticholinergic medications like trihexyphenidyl, which relieve symptoms in the majority of cases within hours. Prompt treatment is important to prevent any long-term effects.
Goldman grand rounds, electroconvulsive therapy (ect)...mysterious rebootLisa E Goldman, MD, MSW
How does ECT work? Is it dangerous? Is it scary? Does it work? What mental health conditions can be effectively treated by ECT? Is it true that ECT works better than prescription antidepressants? What are common side effects of ECT and how are this managed? Has the practice of ECT changed over time? What patient factors are the best predictors of positive and negative outcomes of ECT treatment? Come with me on a journey as I present my grand rounds lecture for the department of psychiatry as I complete my 4th year of psychiatry residency at UTHSC Memphis. These are exciting times. Recovery is definitely an option.
Dr. Claudia Mghazli examines how osteopathic manual therapy can aid with tinnitus, a condition that affects an estimated 10-15% of the global population.
BIOLOGICAL EFFECTS OF RADIATION USHA YADAV.pptxSubamProjects
Basic of human body
What is biological effect of radiation
How radiation can cause biological damage
Factors affecting biological effects
What are classes different biological effects caused by radiation
Acute radiation syndrome
Partial body effects
Cancer and genetic risk
DR SANJAY PHADKE- Introducing Symposium on MIND- BODY MEDICINEDR VANI KULHALLI
The critical importance of mind body medicine as regards
- treatment gap of 80-96pc for mental illness
- proved benefit
- can be administered by non medical professionals
- safe and efficetive
This document summarizes research on oxytocin and its effects on heart rate variability and social behavior. It discusses how oxytocin increases gaze to eye regions and is involved in emotion recognition. Oxytocin has also been shown to increase heart rate variability, which is reduced in conditions like depression and alcohol dependence. The document proposes a placebo-controlled study using oxytocin treatment over 4 weeks for alcohol dependence, measuring outcomes like alcohol intake, social cognition, and psychophysiology. It suggests oxytocin may help disorders with poor social functioning by influencing the autonomic nervous system.
Transcranial magnetic stimulation (TMS) is a non-invasive treatment for major depressive disorder that uses magnetic pulses to stimulate nerve cells in the brain. A review of the efficacy of TMS found that it is an effective alternative or addition to treatments like antidepressants and psychotherapy. TMS works by inducing electric currents in the brain via electromagnetic induction to modulate neuronal activity. It has shown response rates of about 60% in clinical trials with mostly mild side effects like brief scalp discomfort. TMS may help reduce the burden of depression, which is high in India, by providing an additional treatment option.
- Mental depression can now be treated safely without drugs or side effects using a new 5-minute treatment called CellSonic that uses shockwaves.
- Pharmaceutical antidepressants cause permanent brain damage with long-term use and risk drug dependency, whereas CellSonic has no side effects.
- Two professors from Poland reported feeling lifted, relaxed, and happier after CellSonic treatments, indicating it may have antidepressant effects by stimulating neurons in the brain.
Prophylaxis,Treatment of Acute Toxic Radiation Cerebrovascular Syndrome Asso...Dmitri Popov
This document discusses acute cerebrovascular radiation syndrome associated with long-term space flight to Mars. It describes the potential risks of radiation exposure during space travel, including the development of radiation neurotoxins that can disrupt the blood-brain barrier and blood flow. It then presents a grading system for acute cerebrovascular radiation syndrome based on neurological symptoms. Finally, it discusses the roles of cannabinoids and their receptors in potentially helping to prevent or treat the biological effects of radiation exposure.
Protection of humans during long space flight. using cannabis to reduce biol...Dmitri Popov
Protection of humans during long space flight. using cannabis to reduce biological consequences of high doses of radiation, treat stress, anxiety, and depression Associated with Long-term Space Flight to Mars.
Know Alzheimer. Manual de consulta para neurólogosinfobipolar
Los nuevos criterios diagnósticos de la demencia debida a la enfermedad de Alzheimer de la NIA-AA aportan cuatro mejoras principales respecto a los criterios NINCS-ADRDA: 1) no establecen un límite de edad, 2) incluyen el concepto de deterioro cognitivo leve, 3) consideran la conducta como un criterio independiente y 4) incorporan la probabilidad diagnóstica basada en biomarcadores.
Know Alzheimer. Manual para médicos de Atención Primariainfobipolar
Este documento proporciona respuestas a preguntas frecuentes sobre el diagnóstico y manejo de la enfermedad de Alzheimer. En cuanto a las pruebas de laboratorio para el diagnóstico, recomienda realizar análisis básicos como hemograma, ionograma, glucemia, TSH y niveles de vitamina B12, y en función de la clínica otros análisis como folatos, función hepática y renal. No recomienda el cribado poblacional de demencias debido a las limitaciones de las pruebas
The document summarizes updated estimates of the global impact of dementia between 2013 and 2050. It finds that the number of people living with dementia worldwide will increase dramatically from 44 million in 2013 to 135 million in 2050. Most significantly, new data from China and sub-Saharan Africa suggests that prevalence of dementia in those regions has been underestimated, leading to higher projected numbers. By 2050, it is estimated that 71% of people with dementia will be living in low- and middle-income countries, compared to 62% currently. The increasing burden in developing regions underscores the need for a global response to address issues of access to care, treatment, and support worldwide.
Este documento proporciona información sobre un simposio sobre el tratamiento del paciente complejo con trastornos bipolares que se llevará a cabo el 31 de enero de 2014 en Barcelona. Incluye detalles sobre los costos de inscripción, cómo registrarse, la agenda del evento con diferentes mesas y ponencias, y la información de contacto. El simposio abordará temas como el manejo de la complejidad del paciente, la prescripción compleja y el tratamiento del paciente difícil.
The Division of Clinical Psychology Annual Conference 2013 was held on December 5-6 at the Royal York Hotel in York. The conference featured keynote speakers discussing topics such as positive behavior support for people with learning disabilities, social determinants of health for children with intellectual disabilities, and enhancing the impact of parenting interventions. Presentations also covered issues such as preventing institutionalization of children with learning disabilities, mental health and employment, and innovations in treating psychosis. Workshops provided instruction on using social media and Twitter to engage patients and staff.
XXI Symposium Internacional de Controversias en Psiquiatríainfobipolar
Este documento proporciona la lista de ponentes y el programa científico de un simposio internacional sobre actualizaciones y controversias en psiquiatría que se celebrará en Barcelona del 14 al 15 de marzo de 2014. El simposio abordará temas relacionados con el insight en la psicosis y contará con la participación de destacados expertos de España, Reino Unido, Israel y Estados Unidos.
Programa del 9º Encuentro del Foro de Enfermeras de Salud Mentalinfobipolar
Este documento anuncia el 9o Encuentro científico y profesional organizado por el Foro de Enfermeras de Salud Mental de la Comunidad de Madrid/ANESM con motivo del Día Mundial de la Salud Mental. El encuentro se centrará en la salud mental de los adultos mayores y contará con conferencias, mesas redondas y la presentación de un libro y documental. Se llevará a cabo el 9 de octubre de 2013 en el Ilustre Colegio Oficial de Enfermería de Madrid.
El documento describe un programa para un evento titulado "Alternativas de Futuro. El Valor de Nuestros Derechos" que se llevará a cabo el 7 de octubre en el Ministerio de Sanidad, Servicios Sociales e Igualdad. El programa incluye sesiones sobre salud mental hoy y el impacto de la crisis en la atención a la salud mental, con intervenciones de representantes de organizaciones como EAPN-ES, Plataforma Psicología Sin Fronteras y CERMI.
El documento describe el programa científico de un congreso internacional sobre enfermedades neurodegenerativas que se llevará a cabo en Madrid del 23 al 24 de septiembre de 2013, incluyendo sesiones sobre la enfermedad de Alzheimer, Parkinson, Huntington y otras enfermedades; también incluye información sobre la sede, registro e inscripción.
This document provides information about the 13th International Forum on Mood and Anxiety Disorders, which will be held from November 20-22, 2013 in Monaco. It includes the dates to remember, contact information for the organizing secretariat and venue, an overview of the program, the advance scientific program with session titles and speaker information, information on scientific submissions and registration, and forms to register and book accommodations. The forum will focus on topics related to mood and anxiety disorders, including lithium treatment, comorbidities of pain, anxiety and depression, cognition as a treatment target, treatment-resistant depression, and more.
3º Congreso Internacional de Patología Dual 2013infobipolar
Este documento presenta el programa provisional de una conferencia sobre patología dual que tendrá lugar del 23 al 25 de octubre. El miércoles 23 habrá varias sesiones con simposios, talleres y presentaciones sobre temas relacionados con la patología dual como la investigación, la evaluación, la intervención y el abordaje multidisciplinar. Se presentarán nuevos programas educativos y libros sobre el tema.
Programa científico 26 Congreso ECNP Barcelona 2013infobipolar
This document summarizes several scientific sessions taking place at the 26th ECNP Congress dedicated to bipolar disorder. It outlines two satellite symposiums on Sunday and Monday focusing on bipolar disorder, its evolving understanding and multidimensional perspective. It also lists a scientific café on bipolar treatment on Sunday and five symposiums covering topics like the psychopharmacology of bipolar disorder, epigenetics, new targets for treating depression/anxiety, immunogenetics in psychiatric disorders, and genetic implications in bipolar disorder. Each symposium provides details on chairpersons, presentations, presenters, and time/location.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfrightmanforbloodline
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
1. ISAD 2012
th th
18 – 20 April 2012, Royal College of Physicians, London, UK
Day 1: Wednesday, 18th April 2012
07:30 Registration opens in lobby of RCP
08:30 – SYMPOSIUM 1 SYMPOSIUM 2 SYMPOSIUM 3
10:30 Council Chamber Linacre and Sloane Room Wolfson Theatre
Hearts and Minds: the links Bipolar Disorder and Brain Stimulation Methods for
between co morbid Substance Use Disorder Treating Depression – Critical
depression and heart Comorbidity: New Findings Review of Latest Clinical
disease and best treatment Findings and New
Session Chair: Roger Weiss Technological Advances
Session Chair: André Tylee (Harvard Medical School)
(King’s College London) Session Chair: Mark George
(Medical University of South
Carolina)
[S1.1] [S2.1] [S3.1]
08:30 Early findings from the Integrated Group Therapy for What's the latest with the
UPBEAT Cohort Bipolar Disorder and oldest? ECT advances.
André Tylee (King’s College Substance Abuse Harold Sackeim (Columbia
London) Roger Weiss (Harvard Medical University)
School)
[S1.2] [S2.2] [S3.2]
09:00 Treatment of depression in Sleep difficulties in Bipolar New advances with
heart disease Disorder and SUD transcranial magnetic
Chris Dickens Margaret Griffin (Harvard Medical stimulation
(Peninsula College of Medicine School) Klaus Ebmeier (University of
and Dentistry) Oxford)
[S1.3] [S2.3] [S3.3]
09:30 Determinants of Optimizing pharmacotherapy: Vagus Nerve Stimulation
depression in cardiac Bipolar and Alcoholism Michael Trimble (Queen’s Square
patients Ihsan Salloum (University of
Andrew Steptoe (University Miami)
College London)
[S1.4] [S2.4] [S3.4]
10:00 Final analyses of the 2-Year Tx Outcome: Bipolar v. Deep Brain Stimulation
MIND-IT study Depressed Alcoholics Thomas Schlaepfer (John Hopkins
Peter de Jonge Conor Farren (St. Patrick’s Hospital)
(UMCG University of University)
Groningen)
10:30 –
11:00 Tea/Coffee Break, Exhibition and Poster Viewing
11:00 – Plenary Session 1 – Wolfson Theatre
12:00 Chair: Bernard Lerer (Hadassah-Hebrew University Medical Center)
Affective disorders – new economic realities
Martin Knapp (King's College London, Institute of Psychiatry)
12:00 – Lunch Break, Exhibition and Poster Viewing
13:30
1
2. 12:15 – Lundbeck Lunchtime Satellite Symposium
13:25 “Recent Advances in the Management of Bipolar Disorder”
Welcome and Introduction
Allan Young, Professor of Psychiatry, Imperial College London, UK
Pharmacological Basis for the Clinical Effects of Antipsychotics
Andrea Fagiolini, Associate Professor of Psychiatry, University of Siena, Italy
Asenapine in the Treatment of Bipolar Disorder I, Acute and Sustained Effects
Heinz Grunze, Professor of Clinical Psychiatry, Newcastle University, UK
Summary & Closing Remarks
Allan Young, Professor of Psychiatry, Imperial College London, UK
13:30 – SYMPOSIUM 4 SYMPOSIUM 5 SYMPOSIUM 6
15:30 Council Chamber Wolfson Theatre Linacre and Sloane Room
Mood Disorders and Diet and Nutrition: New Psychopharmacology of
Somatic Comorbidity: From Opportunities for the Affective Disorders: Is There a
Associations to Prevention and Treatment of Future?
Mechanisms Moody and Anxiety Disorders
Session Chair: Bernard Lerer
Session Chair: Martin Preisig Session Chair: Felice Jacka (Hadassah-Hebrew University
(University of Lausanne) (Deakin University) Medical Center)
[S4.1] [S5.1] [S6.1]
13:30 Mortality of 406 patients Diet and Nutrition: New Generic SSRIs: The End of
with mood disorders over opportunities for the History?
prevention and treatment of
50 years after admission Phil Cowen (University of Oxford)
mood and anxiety disorders
Jules Angst (University of
across the lifecourse
Zurich) Felice Jacka (Deakin University)
[S4.2] [S5.2] [S6.2]
14:00 Mood disorders, Mediterranean Diet, trans fatty Hormonal Therapies and
cardiovascular risk factors acids and depression. The SUN Antidepressant Development
and inflammatory markers: Project Bernard Lerer (Hadassah-Hebrew
results of a population- Almudena Sánchez-Villegas University Medical Center)
based survery (University of Las Palmas de Gran
Jennifer Glaus (University Canaria)
Hospital Center and University
of Lausanne)
[S4.3] [S5.3] [S6.3]
14:30 Bone quality in mood Dietary patterns and Pharmacogenetics and
disorders depression in Japan Antidepressant Treatment
Lana Williams (Deakin Akiko Nanri (International Clinical Julio Licinio (Australian National
University) Research Center) University)
[S4.4] [S5.4] [S6.4]
15:00 Depression and Obesity Nutritional supplements for Neural plasticity & Novel Mood
Julie Pasco (University of the treatment of mood Disorder Therapies
Melbourne) disorders Husseini Manji (Johnson &
Jerome Sarris (University of Johnson Pharmaceuticals)
Melbourne)
15:30 –
16:00 Tea/Coffee Break, Exhibition and Poster Viewing
2
3. ORAL PRESENTATION ORAL PRESENTATION ORAL PRESENTATION
16:00 – SESSION 1 SESSION 2 SESSION 3
17:30 Linacre and Sloane Room Wolfson Theatre Council Chamber
Session Chair: Elliott Session Chair: Ray Lam Session 3: Anthony Cleare
Richelson (The Mayo Clinic) (University of British Columbia) (Institute of Psychiatry, UK)
[O1.1] [O2.1] [O3.1]
Neurophysiological Physical exercise as an Suicide increased in untreated
predictors of non-response adjuvant therapy for young individuals in Sweden
16:00
to rTMS in Depression depression after "Black BOX" warnings for
Martijn Arns (Brainclinics) Jorge Mota-Pereira "suicidality" as an adverse
effect of antidepressants
Göran Isacsson
[O1.2] [O2.2] [O3.2]
The Relationship Between Aggregation of mood spectrum Computerised CBT for older
Brain Oscillatory Activity disorders in clinical and adults with depression and
and Therapeutic population based families comorbid cardiovascular
16:15
Effectiveness of Caroline Vandeleur disease -a randomised,
Transcranial Magnetic double-blind, placebo
Stimulation in the controlled trial
Treatment of MDD Nick Glozier (Sydney Medical
Andrew Leuchter (UCL) School)
[O1.3] [O2.3] [O3.3]
Relapse rates following a Co-occurring psychopathology Epilepsy and major
successful course of in parents with recurrent depression, bipolar disorder,
electroconvulsive therapy depression and risk to and suicide attempt: Evidence
16:30
for depression: A adolescent offspring for a bidirectional relationship
systematic review and Ruth Sellers (Cardiff University) Dale Hesdorffer (Columbia
meta-analysis University)
Ana Jelovac (Trinity College
Dublin)
[O1.4] [O2.4] [O3.4]
Harsh parenting and neural The Association Between Fruit Impact of co-morbid anxiety
fear circuitry function in and Vegetable Consumption and/or substance use disorder
16:45
high and low anxious and Mental Health Disorders in on outcomes of Psychotherapy
youths: Preliminary Canadians for bipolar disorder
findings Ian Colman(University of Ottawa) Maree Inder
Françoise Maheu (University
of Montréal)
[O1.5] [O2.5] [O3.5]
Change in amygdala and Lessons learned from two Depression and smoking: a
hippocampal volumes after Cochrane Reviews on five-year prospective study of
twelve weeks of paroxetine depression treatments in patients with major depressive
17:00
treatment for major patients with diabetes and disorder
depressive disorder patients with coronary artery Isometsä Erkki (University of
Henricus G Ruhe (University of disease Helsinki)
Amsterdam) Harald Baumeister
[O1.6] [O2.6] [O3.6]
Modifiable lifestyle factors, Randomized clinical trials Protective factors against
depression and underestimate the efficacy of depression during the
17:15
inflammation in the Hunter antidepressants in less severe transition from adolescence to
Community Study depression adulthood: Findings from a
Sarah Hiles Göran Isacsson national Canadian cohort
Ian Colman(University of Ottawa)
3
4. 17:30 – Poster Session
19:00
19:00 – Welcome Reception
20:30
Day 2: Thursday, 19th April 2012
08:30 – SYMPOSIUM 7 SYMPOISUM 8 SYMPOSIUM 9
10:30 Council Chamber Linacre and Sloane Room Wolfson Theatre
Are Specialised Affective Metabolic Depression: A Constitutional Determinants of
Disorder Services Useful? Specific Depression Subtype? Anxiety Disorders:
Physiological and
Session Chair: Chantal Henry Session Chair: Brenda Penninx Neuroimaging Characteristics
(University of Paris) (VU University Medical Cente)
Session Chair: Hugo Critchley
(Brighton and Sussex Medical
School)
[S7.1] [S8.1] [S9.1]
08:30 Canadian Programmes Inflammation, leptin and onset Exaggerated autonomic
Sagar Parikh (University of of depression responses and vulnerability to
Toronto) anxiety
Yuri Milaneschi (National Institutes
of Health) Satoshi Umeda (Keio University)
[S7.2] [S8.2] [S9.2]
09:00 German Algorithm Inflammation, metabolic Early emotional processing
Mazda Adli (Charite- syndrome, depression course and bodily arousal
universitatsmedizin Berlin) Nicole Vogelzangs (VU University) Henrique Sequeira (Lille
University)
[S7.3] [S8.3] [S9.3]
09:30 French network of bipolar Evidence for differential Interoceptive awareness and
expert centres underlying pathophysiology in anxiety
Bruno Etain (INSERM, U 955) melancholic versus atypical (Olga Pollatos)
depression subtypes Universität Potsdam
Femke Lamers (National Institutes Humanwissenschaftliche Fakultät
of Health)
[S7.4] [S8.4] [S9.4]
10:00 ENBREC: European Inflammation and depression Neurobiological pathways
Network of Bipolar Expert symptom profile linking socioeconomic position
Centres Martin Preisig (University of and health
Chantal Henry (University of Lausanne) Peter Gianaros (University of
Paris) Pittsburgh)
10:30 –
11:00 Tea/Coffee Break, Exhibition and Poster Viewing
Plenary Session 2 – Wolfson Theatre
Chair: Jan Scott (Newcastle University)
11:00 – Cognitive Behaviour Therapy in the Treatment and Prevention of Depression
12:00 Steve Hollon (Vanderbilt University, Nashville, USA)
12:00 –
13:30 Lunch Break, Exhibition and Poster Viewing
4
5. 13:30 – ORAL PRESENTATION ORAL PRESENTATION ORAL PRESENTATION
15:30 SESSION 4 SESSION 5 SESSION 6
Council Chamber Linacre and Sloane Room Wolfson Theatre
Session Chair: Roger Pinder Session Chair: Allan Young
(ISAD Immediate Past (Imperial College London)
President)
[O4.1] [O5.1] [O6.1]
The role of meaning in life Timing of First Exposure to Gender differences in response
13:30 in promoting resiliency to Maternal Depression and to terrorist attacks: from
late-life suicide ideation Adolescent Emotional Disorder initial response to treatment
Marnin J. Heisel (Victoria
in a National Canadian Cohort response
Hospital)
Ian Colman (University of Ottawa) Sara Freedman (Bar Ilan Univ)
[O4.2] [O5.2] [O6.2]
Age of onset and the Prevention of depression in at- Circadian rhythms in
13:45 prospectively observed risk adolescents menopausal depression
course of illness in bipolar Judy Garber (Vanderbilt Barbara Parry (University of
disorder University) California, San Diego)
William Coryell
[O4.3] [O5.3] [O6.3]
Interaction between Predictors of children's Lifetime comorbidity of major
MTHFR C677T posttraumatic stress and depression and anxiety
14:00 Polymorphism and depression after a natural disorders among a community-
traumatic childhood events
disaster: Gene by environment based sample of women:
predicts recurrence in
recurrent MDD: a 5,5-year interactions clinical correlates and
prospective study Annette La Greca (University of psychosocial features
Anja Lok (University of Miami) Jill M. Cyranowski (University of
Amsterdam) Pittsburgh Medical Center)
[O4.4] [O5.4] [O6.4]
P2RX7: Expression Stress and depression in a Trajectories of maternal
Responds to Sleep population sample of symptoms of anxiety and
14:15 Deprivation and Associates adolescents (TRAILS): the depression over 13 years:
with Rapid Cycling in
risks and benefits of exposure The influence of stress, social
Bipolar Disorder Type 1
to childhood adversities support, and maternal
Lena Backlund
Albertine Oldehinkel temperament
Anni Skipstein (Norwegian
Institute of Public Health)
[O4.5] [O5.5] [O6.5]
Longitudinal hypothalamic- Psychotic symptoms index The BraveHeart project:
pituitary-adrenal axis trait ultra-high risk for suicidal randomised controlled trial of
14:30 and state effects in behaviour in young people group cognitive behaviour
recurrent depression
with affective disorders therapy versus brief
Roel JT Mocking (University of
Amsterdam) Ian Kelleher intervention for depression in
cardiac patients
Amanda Baker (University of
Newcastle, Australia)
[O4.6] [O5.6] [O6.6]
Suicide and brain chemical Depressive problems and Preventive cognitive therapy
14:45 changes with altitude academic performance, social in recurrent depression: a 10
Perry F. Renshaw well-being, and social year follow-up of the DELTA
problems in adolescence: study
Longitudinal and bidirectional Aart H. Schene (University of
effects Amsterdam)
Charlotte Verboom
5
6. [O4.7] [O5.7] [O6.7]
15:00 Investigation of reward as Childhood stress-reactivity and A Randomized Controlled Trial
a neural biomarker for Inflammatory Mechanisms in of Psychoeducation or
depression Major Depressive Disorder Cognitive-Behavioural Therapy
Ciara McCabe (Oxford
Sarah Cohen-Woods (King’s in Bipolar Disorder: A CANMAT
University)
College London) Study
Sagar Parikh (University of
Toronto)
[O4.8] [O5.8] [O6.8]
Genetic polymorphisms, Identifying clinical risk What makes people persist
15:15 hopelessness and suicidal markers for depression in high with internet interventions for
risk in a sample of subjects risk offspring depression?
with chronic migraine and
Becky Mars (Cardiff University) Liesje Donkin
affective temperamental
dysregulation
Gianluca Serafini
15:30 –
16:00 Tea/Coffee Break, Exhibition and Poster Viewing
16:00 –
17:30 Poster Session ISAD AGM
19:30 Gala Dinner (Ironmonger’s Hall, City of London)
6
7. Day 3: Friday, 20th April 2012
Plenary Session 3 – Wolfson Theatre
08:30 – Chair: Sidney Kennedy (ISAD President)
09:30 Epigenetic basis for the transgenerational transmission of individual differences in
vulnerability for psychopathology
Professor Michael Meaney (McGill University, Montreal, Quebec, Canada)
09:30 – SYMPOSIUM 10 SYMPOSIUM 11 SYMPOSIUM 12
12:00 Linacre and Sloane Room Wolfson Theatre Council Chamber
International Society for Can we Identify those at Risk The Early Identification of Risk
Bipolar Disorders: Task of Unipolar and Bipolar for Affective Illness: Findings
Force Updates Disorders? from the Orygen Adolescent
Development Study
Session Chair: Sophia Session Chair: Jan Scott
Frangou (King’s College (Newcastle University) Session Chair: Nicholas Allen
London) (The University of Melbourne)
[S10.1] [S11.1] [S12.1]
Women's Task Force: Case finding strategies to Brain development and
Physical and Endocrine augment the early adolescent onset depression
09:30
Health in Women with identification of bipolar Sarah Whittle (The University of
Bipolar Disorder disorders Melbourne)
Aysergul Ozerdem (Dokuz Jan Scott (Newcastle University)
Eylul University Medical
School)
[S10.2] [S11.2] [S12.2]
Clinical Trials Task Force: Is there any biomarker for Family processes as predictors
10:00 Challenges & new bipolarity? of teen depression
directions in clinical trials Marion Leboyer (University of Orli Schwartz (The University of
design for Bipolar Disorder Paris) Melbourne)
Lakshmi Yatham (The
University of British Columbia)
10:30 – Tea/Coffee Break, Exhibition and Poster Viewing
11:00
[S10.3] [S11.3] [S12.3]
Neuroimaging Task Force: Neuroendocrine and other Depressive symptoms and
11:00 Neural Correlates of predictors of depression C-reactive protein in
Bipolar Disorder: What Ian Hickie (University of Sydney) adolescents: Effects of sex
have we learned so far? Michelle Byrne (The University of
Melbourne)
Sophia Frangou (King’s
College London)
[S10.4] [S11.4] [S12.4]
Biomarkers for patients Lifestyle as a risk factor for Affective Psychophysiology
11:30 with Bipolar Disorder: depression; A neglected and integration.
ISBD Taskforce Perspective opportunity for prevention? Nicholas Allen (The University of
Trevor Young (University of Michael Berk (Universities of Melbourne)
Toronto) Melbourne & Deakin)
12:00 Close of Meeting
Please note that speakers and presentation titles are subject to change at short notice
7